Drugs / HS-10370
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06963502 | May 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06594874 | Oct 2024 → Oct 2026 expected | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05367778 | Jun 2022 → Apr 2025 overdue | neoplasm | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10370 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05367778 ↗ |
| Action | Inhibit | “inhibitor of KRAS G12C” NCT05367778 ↗ |
| Modality | Small molecule | “HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C.” NCT05367778 ↗ |
| Route | Oral | “HS-10370 will be administered orally once daily in a continuous regimen” NCT05367778 ↗ |
| Target | KRAS | “inhibitor of KRAS G12C” NCT05367778 ↗ |